August 08, 2023 – Everest Pharma is proud to announce the launch of RUXOTOR Cream, a generic version of the FDA-approved OPZELURA (Ruxolitinib Cream 1.5%), offering a significant advancement in the topical treatment of non-segmental vitiligo and mild-to-moderate atopic dermatitis.
RUXOTOR Cream contains Ruxolitinib, a Janus kinase (JAK) inhibitor that modulates immune signaling by selectively targeting JAK1 and JAK2 pathways. It is indicated for adults and pediatric patients aged 12 years and older with non-segmental vitiligo or mild-to-moderate eczema who are not adequately controlled with topical therapies or when those therapies are not advisable.
By launching this cost-effective alternative to OPZELURA, Everest Pharma is taking another step forward in its mission to expand global access to high-quality, innovative treatments—especially in regions where affordability remains a challenge.
“We are proud to bring RUXOTOR Cream to market as a trusted, affordable option for patients living with chronic skin conditions,” said Mr. Md. Zakir Hossain, Managing Director of Everest Pharma. “This launch highlights our dedication to therapeutic innovation, access, and quality—particularly in dermatology.”
The availability of RUXOTOR CREAM (Generic of OPZELURA) is expected to strengthen Everest Pharma in its position as a pioneer in dermatologic care and high-quality topical therapies.
About Everest Pharma:
Everest Pharma is a globally recognized pharmaceutical company committed to offering high-quality, affordable generic medicines. With a focus on innovation and access, the company continues to develop essential therapies across a range of therapeutic areas to improve patient outcomes worldwide.
For more information on RUXOTOR CREAM and Everest Pharma’s portfolio, visit https://www.ruxotor.com/ or https://www.everestpharmabd.com/